Monday, March 17, 2025 | 09:35 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Granules India receives USFDA approval for Amphetamine Mixed Salts IR Tablets

Image

Capital Market
Granules India announced today that the US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of Granules India, for Amphetamine Mixed Salts, USP 1.25mg, 1.875mg, 2.5mg, 3.125mg, 3.75mg, 5mg, 7.5mg Immediate-Release Tablets. It is bioequivalent to the reference listed drug product (RLD), _Adderall of Teva Women's Health Inc. The product would be available for the US market shortly.

Granules now have a total of 47 ANDA approvals from the US FDA (45 Final approvals and 2 tentative approvals).

Powered by Capital Market - Live News

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Dec 30 2021 | 10:20 AM IST

Explore News